Ivabradine and the SIGNIFY conundrum

Abstract

This editorial refers to ‘Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: the SIGNIFY study’, by K.M. Fox et al., on page doi:10.1093/eurheartj/XXX Stable angina is a prevalent and disabling condition that occurs in 10–14% of those aged 65–84 years,1 with population studies suggesting that almost a third of affected patients experience an angina episode at least once a week.2 Treatment focuses upon the alleviation of angina symptoms and the prevention of cardiac events. Although the development of cardioprotective agents has received considerable attention in recent years, there has been less progress with novel antianginal agents.